The US Court of Appeals for the Third Circuit concludes that the Actavis ruling applies to non-cash payments (Lamictal)

On June 26, 2015, in the first federal appellate drug patent settlement ruling since the Supreme Court’s decision in FTC v. Actavis, 133 S. Ct. 2223 (2013), the U.S. Court of Appeals for the Third Circuit overturned a lower court decision granting a motion to dismiss for defendants. Writing for a unanimous panel, Judge Anthony Scirica unequivocally found that Actavis applied to not only cash payments but also other forms of consideration including brand-firm promises not to introduce “authorized generics” that would compete with true generics. Background The case involves Lamictal, a drug that treats epilepsy and bipolar disorder. King Drug Co. of Florence v. Smithkline Beechham Corp., 791 F.3d 388, 396 (3d Cir. 2015). GlaxoSmithKline (GSK) obtained a patent, expiring in 2008, that

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

Michael A. Carrier, The US Court of Appeals for the Third Circuit concludes that the Actavis ruling applies to non-cash payments (Lamictal), 26 juin 2015, e-Competitions June 2015, Art. N° 75208

Visites 404

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues